Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer.

Phase I clinical and pharmacokinetic study of protein kinase C-alpha antisense oligonucleotide ISIS 3521 administered in combination with 5-fluorouracil and leucovorin in patients with advanced cancer. Clin Cancer Res. 2002 Apr; 8(4):1042-8.

View in: PubMed

subject areas

Adult
Aged
Antineoplastic Combined Chemotherapy Protocols
Area Under Curve
Diarrhea
DNA, Antisense
Dose-Response Relationship, Drug
Drug Therapy, Combination
Fatigue
Female
Fluorouracil
Humans
Isoenzymes
Leucovorin
Male
Middle Aged
Nausea
Neoplasms
Neutropenia
Oligonucleotides
Protein Kinase C
Protein Kinase C-alpha
Thionucleotides
Thrombocytopenia
Treatment Outcome
Vomiting

authors with profiles

Hedy Kindler
Mark J. Ratain